(Reuters) – Exonosens reported on Monday of 18% growth in turnover in the first quarter at exchange rate and constant perimeter, carried by the strong growth of its amplification segment on the background of demand sustained in the field of defense.

Over the first three months of the year, Exoseens recorded a turnover of 104.9 million euros after 86.7 million euros the previous year. The analysts interviewed by Reuters tapped on a turnover of 101 million euros.

Exosers, which made its IPO in June and joined the SBF 120 last month, also reported a 28.1% jumper of its adjusted gross margin, which was established at 52.6 million euros in the quarter.

Its amplification segment, which produces the night vision systems Photonis, saw its turnover increase by 29.3% compared to 2024.

“With regard to our defense -related activities, demand remains high in a context of growing geopolitical tensions and supported investments on the part of NATO countries and their main allies,” said Jérôme Cerisier, director general, in a statement.

Since Donald Trump began his mandate in January, many European countries reaffirmed their support for Ukraine and have committed to increase their expenses in the defense field. In this context, in March, the European Union presented a “rearmament plan” aimed at mobilizing 800 billion euros to build the capacities of twenty-seven in the sector.

Exosers, which notably provides its night vision systems to NATO and also operates within the framework of nuclear and medical research, is considered a strategic asset by France, which blocked the sale to an American conglomerate five years ago.

The group has also confirmed its prospects for 2025, namely growth in turnover at the top of the range 15-20% and an EBITDA growth adjusted at the bottom of the range 20-25% compared to the year 2024.

(Written by Pauline Foret, edited by Kate Entringer)

Copyright © 2025 Thomson Reuters